BioCentury
ARTICLE | Clinical News

Sembragiline: Phase IIb data

July 13, 2015 7:00 AM UTC

The double-blind, international Phase IIb MAyflOwer RoAD trial in about 544 patients with moderate severity AD on stable background therapy showed that oral sembragiline missed the primary endpoint of...